Literature DB >> 20960254

Anti-EGFR-miniantibody-barnase immunoconjugate is highly toxic for human tumor cells.

E F Edelweiss1, T G Balandin, O A Stremovskiy, S M Deyev, R V Petrov.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20960254     DOI： 10.1134/S1607672910050133

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN： 1607-6729            Impact factor:   0.788


× No keyword cloud information.
  12 in total

1.  Binase and other microbial RNases as potential anticancer agents.

Authors:  Alexander A Makarov; Alexander Kolchinsky; Olga N Ilinskaya
Journal:  Bioessays       Date:  2008-08       Impact factor: 4.345

2.  A dimeric bispecific miniantibody combines two specificities with avidity.

Authors:  K M Müller; K M Arndt; A Plückthun
Journal:  FEBS Lett       Date:  1998-07-31       Impact factor: 4.124

Review 3.  [Antibody engineering: barnase-barstar module as a molecular constructor].

Authors:  S M Deev; E N Labedenko
Journal:  Bioorg Khim       Date:  2009 Nov-Dec

Review 4.  Epidermal growth factor receptor targeting in cancer.

Authors:  John Mendelsohn; Jose Baselga
Journal:  Semin Oncol       Date:  2006-08       Impact factor: 4.929

Review 5.  Barnase and barstar: two small proteins to fold and fit together.

Authors:  R W Hartley
Journal:  Trends Biochem Sci       Date:  1989-11       Impact factor: 13.807

6.  Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects.

Authors:  U Rodeck; M Herlyn; D Herlyn; C Molthoff; B Atkinson; M Varello; Z Steplewski; H Koprowski
Journal:  Cancer Res       Date:  1987-07-15       Impact factor: 12.701

7.  Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition.

Authors:  Heidi A Erickson; Michelle D Jund; Christopher A Pennell
Journal:  Protein Eng Des Sel       Date:  2005-10-21       Impact factor: 1.650

8.  Epidermal growth factor receptor-dependent cytotoxic effect by an EGF-ribonuclease conjugate on human cancer cell lines--a trial for less immunogenic chimeric toxin.

Authors:  H Jinno; M Ueda; S Ozawa; K Kikuchi; T Ikeda; K Enomoto; M Kitajima
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

9.  Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.

Authors:  Sergey M Deyev; Ekaterina N Lebedenko
Journal:  Bioessays       Date:  2008-09       Impact factor: 4.345

10.  Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome.

Authors:  A M Soler-Rodríguez; M A Ghetie; N Oppenheimer-Marks; J W Uhr; E S Vitetta
Journal:  Exp Cell Res       Date:  1993-06       Impact factor: 3.905
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.